Tiziana Life Sciences – Files Registration Statement on Form F-3 with SEC January 27, 2021 – Posted in: Tiziana Life Sciences (TILS)

27th January, 2021 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces that it has filed a “universal” shelf registration statement on Form F-3 (File No. 333-252441) (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in relation to…

Tiziana Life Sciences – Updated Corporate Presentation January 26, 2021 – Posted in: Tiziana Life Sciences (TILS)

26 January 2021 Updated corporate presentation Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, has today published an updated presentation to its website at https://ir.tizianalifesciences.com/presentation providing an update with respect to an overview of its current clinical pipeline. The presentation contains no new material information but gives an overview of all of the Company’s current and active development…

Tiziana Life Sciences – AIM Delisting and Admission to the Standard Listing Segment of Main Market January 20, 2021 – Posted in: Tiziana Life Sciences (TILS)

20th January, 2021 Tiziana Life Sciences plc (“Tiziana” or the “Company”) AIM Delisting and Admission to the Standard Listing Segment of Main Market Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM and admission to listing of its ordinary…

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer January 13, 2021 – Posted in: Tiziana Life Sciences (TILS)

13th January, 2021 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer. Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist…

Tiziana Life Sciences to Host Investor Update Call December 1, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET NEW YORK and LONDON – 1 December 2020 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO Dr. Kunwar Shailubhai will host a conference call on Wednesday, 2 December 2020 at 4:15 p.m. ET to provide updates on…

Tiziana Life Sciences – Phase 1b/2 Clinical Trial – Crohn’s Disease November 11, 2020 – Posted in: Tiziana Life Sciences (TILS)

11th November, 2020 Tiziana Life Sciences PLC (“Tiziana” or “the Company”) Phase 1b/2 Clinical Trial – Crohn’s Disease Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease First Ever Study with take-home capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody – Potential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease -Crohn’s Disease Therapeutics Market Size $4.7 Billion by…

Tiziana Life Sciences – Demerger Update and Timetable Confirmation October 29, 2020 – Posted in: Tiziana Life Sciences (TILS)

29th October, 2020 Tiziana Life Sciences PLC (“Tiziana” or the “Company”) Demerger Update and Timetable Confirmation Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that the capital reduction required to effect the demerger of StemPrintER Sciences Limited and to enable the ultimate allotment of Accustem Sciences Limited shares (the “Demerged Shares”) to shareholders in the…

(No title) October 21, 2020 – Posted in: Tiziana Life Sciences (TILS)

21st October, 2020 Tiziana Life Sciences Plc (“Tiziana” or the “Company”) Exercise of options, Issue of Equity PDMR Dealing and Total Voting Rights Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and issued total of 1,750,000 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid; (i) in…

Tiziana Life Sciences – Issue of Equity on Exercise of Warrants October 20, 2020 – Posted in: Tiziana Life Sciences (TILS)

20th October, 2020 Tiziana Life Sciences Plc (“Tiziana” or the “Company”) Issue of Equity on Exercise of Warrants Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and issued 35,714 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid at a price of 70 pence per share in…

Tiziana Life Sciences – Interim Results for Six Months ended 30th June 2020 September 30, 2020 – Posted in: Uncategorized

30th September, 2020 Tiziana Life Sciences plc (“Tiziana” or “the Company”) Interim Results for the Six Months Ended 30 June 2020 Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA), a biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases today announces its interim results…

1
2
3
4
Next
Last »